KPC Pharmaceuticals,Inc. (SHA:600422)
China · Delayed Price · Currency is CNY 12.30
+0.04 (0.33%)
Feb 3, 2026, 3:00 PM CST
KPC Pharmaceuticals,Inc. Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Jan '21 Jan 1, 2021 |
Operating Revenue | 6,911 | 7,960 | 8,266 | 7,720 | 8,045 | 7,606 |
Other Revenue | 441.93 | 441.93 | 163.98 | 562.24 | 208.77 | 110.76 |
| 7,353 | 8,401 | 8,430 | 8,282 | 8,254 | 7,717 | |
Revenue Growth (YoY) | -14.70% | -0.34% | 1.79% | 0.35% | 6.95% | -4.96% |
Cost of Revenue | 4,390 | 4,771 | 4,544 | 4,855 | 4,865 | 4,409 |
Gross Profit | 2,962 | 3,631 | 3,886 | 3,427 | 3,389 | 3,308 |
Selling, General & Admin | 2,281 | 2,597 | 2,983 | 2,812 | 2,779 | 2,665 |
Research & Development | 110.26 | 106.76 | 94.2 | 69.65 | 100.52 | 128.45 |
Other Operating Expenses | 97.63 | 81.5 | 84.64 | -57.25 | 64.56 | -7.63 |
Operating Expenses | 2,500 | 2,831 | 3,206 | 2,864 | 2,980 | 2,793 |
Operating Income | 462.38 | 800.18 | 679.83 | 563.54 | 409.19 | 515.53 |
Interest Expense | -47.39 | -26.36 | -21.61 | -40.73 | -33.59 | -29.16 |
Interest & Investment Income | 13.41 | 27.78 | 38.14 | 12.05 | 156.1 | 23.43 |
Currency Exchange Gain (Loss) | 1.92 | 1.92 | 2.08 | 3.08 | -3.48 | -6.38 |
Other Non Operating Income (Expenses) | 5.61 | 13.16 | 7.55 | -27.97 | -7.25 | -12.36 |
EBT Excluding Unusual Items | 435.93 | 816.67 | 705.99 | 509.97 | 520.97 | 491.06 |
Gain (Loss) on Sale of Investments | 127.75 | 6.92 | 1.03 | 10.67 | -0.96 | -1.36 |
Gain (Loss) on Sale of Assets | 0.77 | 1.01 | 1.04 | 15.21 | 2.2 | 51.29 |
Asset Writedown | 5.67 | -2.04 | -30.12 | -57.73 | -0.29 | -0.36 |
Other Unusual Items | 112.01 | 112.01 | 108.45 | -0.84 | 109.37 | -0.14 |
Pretax Income | 682.13 | 934.57 | 786.38 | 477.29 | 631.29 | 540.49 |
Income Tax Expense | 110.94 | 183.35 | 143.7 | 91.83 | 118.07 | 78.3 |
Earnings From Continuing Operations | 571.2 | 751.22 | 642.67 | 385.46 | 513.21 | 462.18 |
Minority Interest in Earnings | -98.36 | -103.14 | -101.96 | -2.28 | -5.55 | -5.33 |
Net Income | 472.84 | 648.08 | 540.71 | 383.18 | 507.67 | 456.86 |
Net Income to Common | 472.84 | 648.08 | 540.71 | 383.18 | 507.67 | 456.86 |
Net Income Growth | -21.10% | 19.86% | 41.11% | -24.52% | 11.12% | 0.56% |
Shares Outstanding (Basic) | 750 | 754 | 762 | 751 | 758 | 759 |
Shares Outstanding (Diluted) | 750 | 754 | 762 | 751 | 758 | 759 |
Shares Change (YoY) | -1.15% | -1.05% | 1.36% | -0.84% | -0.19% | -0.33% |
EPS (Basic) | 0.63 | 0.86 | 0.71 | 0.51 | 0.67 | 0.60 |
EPS (Diluted) | 0.63 | 0.86 | 0.71 | 0.51 | 0.67 | 0.60 |
EPS Growth | -20.18% | 21.13% | 39.22% | -23.88% | 11.33% | 0.89% |
Free Cash Flow | 521.6 | 728.63 | 644.69 | 152.15 | 15.46 | 251.21 |
Free Cash Flow Per Share | 0.70 | 0.97 | 0.85 | 0.20 | 0.02 | 0.33 |
Dividend Per Share | 0.300 | 0.300 | 0.200 | 0.160 | 0.270 | 0.230 |
Dividend Growth | 50.00% | 50.00% | 25.00% | -40.74% | 17.39% | 15.00% |
Gross Margin | 40.29% | 43.22% | 46.10% | 41.38% | 41.06% | 42.87% |
Operating Margin | 6.29% | 9.52% | 8.06% | 6.80% | 4.96% | 6.68% |
Profit Margin | 6.43% | 7.71% | 6.41% | 4.63% | 6.15% | 5.92% |
Free Cash Flow Margin | 7.09% | 8.67% | 7.65% | 1.84% | 0.19% | 3.26% |
EBITDA | 618.98 | 964.84 | 855.23 | 744.03 | 568.04 | 666.42 |
EBITDA Margin | 8.42% | 11.48% | 10.14% | 8.98% | 6.88% | 8.64% |
D&A For EBITDA | 156.6 | 164.66 | 175.4 | 180.49 | 158.86 | 150.89 |
EBIT | 462.38 | 800.18 | 679.83 | 563.54 | 409.19 | 515.53 |
EBIT Margin | 6.29% | 9.52% | 8.06% | 6.80% | 4.96% | 6.68% |
Effective Tax Rate | 16.26% | 19.62% | 18.27% | 19.24% | 18.70% | 14.49% |
Revenue as Reported | 7,353 | 8,401 | 8,430 | 8,282 | 8,254 | 7,717 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.